Drug intelligence / Profile preview

Rho-PSP5

Development stage: Unknown
Lead developer: Revere Pharmaceuticals
Modality: Small Molecules

Overview

Rho-PSP5 is a small molecule therapeutic candidate being developed by Revere Pharmaceuticals for the treatment of cancer metastases. It specifically targets the Rho family of small GTPases, which are key regulators of the actin cytoskeleton and are involved in cell migration, adhesion, and invasion—processes essential for the metastatic spread of tumors. By modulating Rho signaling, Rho-PSP5 is designed to inhibit the movement and colonization of cancer cells. The program is currently in the discovery stage of development.

Targets

RHOA (Ras homolog gene family member A)

Beyond the preview

Go deeper on Rho-PSP5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rho-PSP5.

Explore the full profile